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pasteur.fr (M. Lecuit)Lymphoid cell plasticity and responsivenessNon-Hodgkin lymphomas (NHLs) arise from malignant trans-
formation of mature lymphocytes. The pathophysiology of NHL
is complex, but major advances in the last two decades have
shed light on several aspects of the mechanisms involved in
lymphoid transformation, in particular in the subgroup of
infection-associated lymphoma.
The incidence of NHL dramatically increased during the sec-
ond half of the twentieth century, and nearly doubled between
1974 and 2009, reaching approximately 20 cases per 100 000
person-years. Although the human immunodeﬁciency virus
(HIV) pandemic (approximately 6% of NHLs occur in HIV-
infected individuals) probably had a signiﬁcant impact on the
epidemiology of NHL, it is not the sole factor [1].Clinical Microbiology and Infection © 2015 European Society of CLymphocytes are specialized cells that respond to external
stimuli (antigens) and host stimuli (receptor-mediated signal-
ling), and acquire various effector functions that culminate in
the elimination of non-self antigens (pathogens, infected and/
or transformed host cells, and allogeneic cells). This property
of recognizing and eliminating non-self antigens is balanced by
mechanisms that enable tolerance to self antigens, in order to
maintain homeostasis. Lymphocytes somatically rearrange
parts of their genome (VDJ recombination of the immuno-
globulin (Ig) and T-cell receptor loci), leading to the acquisi-
tion of a diverse repertoire of antigen receptors. In B-cells, Ig
gene recombination occurs during the early phase of pre-
cursor B-cell development in the bone marrow. Immature B-
cells bearing a surface Ig (B-cell receptor (BCR)) exit the bone
marrow, and complete their maturation in peripheral
lymphoid organs along two main pathways [2]. Ultimately,
two B-cell subsets are recognized: marginal zone (MZ) B-cells
and follicular (FO) B-cells. MZ B-cells are localized within the
MZ of lymphoid organs (lymph nodes and spleen), and
participate in T-cell-independent responses. FO B-cells
represent the major B-cell subset, and participate in T-cell-
dependent responses in germinal centres (GCs). FO B-cells
undergo a second step of somatic gene rearrangement during
the GC reaction. Somatic hypermutations target theClin Microbiol Infect 2015; 21: 991–997
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heavy and light chains respectively, generating antibodies with
higher afﬁnity for the antigen upon subsequent exposure.
Class-switch recombination changes the constant region of
the Ig, generating new isotypes with similar variable regions.
As for VDJ recombination, somatic hypermutations and class-
switch recombination both involve double-strand DNA
breaks that are secondarily repaired. Unlike B-cells, T-cells
undergo only one period of somatic VDJ recombination of the
T-cell receptor locus in the thymus. Given the ability of
lymphocytes to somatically rearrange their genomes, both B-
cells and T-cells are intrinsically prone to genetic instability
and malignant transformation. Moreover, the extended life-
span of numerous lymphocyte subsets, particularly memory
cells, and constant re-exposure to antigen-driven activation
and proliferation increase the risk of malignant
transformation.Mechanisms of lymphoid transformationNumerous molecular pathways are deregulated in lymphomas.
Studies based on transcriptome, comparative genomic hy-
bridization array and, more recently, whole genome
sequencing of different lymphoma subtypes have characterized
many recurrent genetic alterations [3]. Pathways involving
cellular activation, nuclear factor-κB (NF-κB) and apoptosis can
be deregulated by loss-of-function or gain-of-function muta-
tions, gene ampliﬁcations, and/or gene translocations. Gene
signatures speciﬁc to certain subtypes of NHL are now deﬁned.
The role of BCR stimulation in B-cell lymphomagenesis is
supported by several lines of evidence [4]. Oncogenic muta-
tions targeting several signalling pathways utilized by normal B-
cells are found in the majority of B-cell lymphomas. NF-κB
activation is central to immune activation, and its activation by
several recurrent mutations is possibly the most important
alteration in B-cell lymphomagenesis [5]. NF-κB is normally
activated through several cell receptors on B-cells (BCRs, B-
cell activating factor receptors, and Toll-like receptors). Mu-
tations leading to constitutive NF-κB signalling are found in
many different types of NHL. Interestingly, in cases where
mutations in the NF-κB pathways are absent, NF-κB activation
by upstream receptors is frequently detected. Normal B-cells
require tonic BCR signalling for their survival. Some subsets of
NHL (activated B-cell type diffuse large B-cell lymphoma
(DLBCL)) rely on a so-called chronic active BCR signal for
their survival. In such cases, inhibition of the BCR pathway by
ibrutinib (Bruton’s tyrosine kinase inhibitor) or idelalisibClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect(phosphoinositide 3-kinase inhibitor) is effective, unless
downstream mutations activating NF-κB are present (such as
CARD11 mutations, which are found in approximately 10% of
activated B-cell type DLBCLs) [4,6].General mechanisms of infection-associated
NHLDirect transformation by pathogens: The case of
Epstein–barr virus and human T-lymphotropic virus 1
Several NHL subtypes are associated with chronic infections.
Epstein–Barr virus (EBV) was the ﬁrst described human
oncogenic virus [7]. Like members of the Herpesviridae, EBV has
a lytic phase and a latent phase of infection. To establish latency,
EBV speciﬁcally targets B-cells, where it is maintained indeﬁ-
nitely as an episome [8]. EBV-infected B-cells undergo activation
and differentiation driven by the ﬁnely tuned expression of viral
latent genes that hijack important cellular functions [9]. Ulti-
mately, EBV-infected B-cells differentiate into resting memory
B-cells harbouring latent EBV with very restricted gene
expression [10]. The natural history of the EBV cycle in B-cells
can sometimes go off-track, leading infected B-cells to prolif-
erate under the control of viral oncogenes and progress to B-
cell lymphomas [11]. Human T-lymphotropic virus 1 (HTLV-1)
was the ﬁrst described human oncogenic retrovirus. It is asso-
ciated with adult T-cell leukaemia/lymphoma, a very aggressive
form of T-cell malignancy [12]. HTLV-1-associated lymphoma-
genesis differs signiﬁcantly form EBV-associated lymphoma-
genesis, but a common feature is the fact that transformed cells
harbour the transforming pathogen, and oncogenesis is driven
by viral factors within the transformed cells.
NHL and HIV
Infection with HIV constitutes one of the most important risk
factors for lymphomas [1]. However, HIV is not directly
oncogenic. The majority of lymphomas occurring in HIV-
infected patients are derived from B-cells. HIV does not,
however, infect B-cells. The mechanisms of lymphoid trans-
formation during HIV infection involve distinct pathways [13].
HIV infection facilitates active chronic infection by other known
direct oncogenic pathogens, such as EBV and human herpes-
virus 8. Immunosuppression associated with HIV may
contribute to virus-induced lymphomagenesis by these patho-
gens through deregulation of their gene expression pro-
grammes. HIV infection also leads to a state of chronic
stimulation of the immune system, which favours the occur-
rence of oncogenic mutations in lymphocytes. The latter mayious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 991–997
CMI Suarez and Lecuit Infection-associated non-Hodgkin lymphomas 993also be ampliﬁed by genetic instability induced by the byprod-
ucts of inﬂammation, such as reactive oxygen species.Indirect transformation of lymphocytes by
non-lymphotropic pathogensIn 1991, Wotherspoon reported the seminal epidemiological
observation that gastric mucosa-associated lymphoid tissue
(MALT) lymphoma is associated with chronic Helicobacter pylori
infection [14]. Since this ﬁrst report, the pathogenesis of
H. pylori-associated gastric MALT lymphoma has been widely
investigated. A ﬁrst major breakthrough came with the
description of the regression of gastric MALT lymphoma after
H. pylori eradication [15]. These observations showed, for the
ﬁrst time, that lymphomas could be driven by non-
lymphotropic pathogens.
Gastric MALT lymphoma is an indolent B-cell lymphoma. It is
the most common lymphoma derived from MALT, and the
most common lymphoma involving the stomach. Indolent
gastric MALT lymphoma can transform into aggressive B-cell
lymphoma of the stomach. In some cases, aggressive B-cell
lymphomas of the stomach can occur without a preceding
indolent episode. Such cases may have an associated histologi-
cally low-grade component and correspond to transformed
indolent gastric MALT, or be devoid of a low-grade component
and represent de novo aggressive B-cell lymphomas of the
stomach. Regardless of the presence of a low-grade compo-
nent, some aggressive gastric B-cell lymphomas can regress, at
least partially, upon H. pylori eradication [16].
MALT lymphomas can develop in various anatomical sites, and
in some cases can be associated with infection. Ocular adnexal
MALT lymphoma has been associated with Chlamydophila psittaci
infection, although this appears to depend strongly on the
geographical origin of patients [17]. Immunoproliferative small-
intestine disorder, also called α-heavy chain disease or Mediter-
ranean lymphoma, corresponds to a MALT lymphoma involving
the lymphoid tissue of the small intestine. The cases of immuno-
proliferative small-intestine disorder studied so far have all been
shown to be associatedwithCampylobacter jejuniorCampylobacter
coli infection [18,19]. Chronic infection with H. pylori may also
favour the development of extragastric and, particularly, ocular
adnexal MALT lymphomas [20]. Finally, Borrelia burgdorferi has
been associated, although not as conclusively as for the H. pylori
association with gastric MALT lymphoma, with cutaneous indo-
lent B-cell lymphoma resembling MALT lymphoma [21,22].
Hepatitis C virus (HCV) is a widely distributed RNA virus of
the Flaviridae family, infecting >170 million people worldwide.
Besides chronic hepatitis, cirrhosis, and an increased risk ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyhepatocellular carcinoma, HCV has been associated with
several extrahepatic manifestations. Mixed cryoglobulinaemia is
associated with chronic HCV infection in >95% of cases [23].
Splenic lymphoma with villous lymphocytes is an indolent B-cell
lymphoma corresponding to a variant of splenic marginal zone
lymphoma. The ﬁrst association of HCV with lymphoma came
with the description of HCV-associated splenic lymphoma with
villous lymphocytes [24,25]. There is a strong epidemiological
association between chronic HCV infection and B-cell lym-
phomas of various subtypes, mostly MZ B-cell lymphomas and
DLBCLs [26–28]. HCV eradication is associated with regres-
sion of a high proportion of such lymphomas [24,25,29], arguing
for a causal role of HCV in B-cell lymphomagenesis.Mechanisms involved in infection-associated
NHLDirect transformation
EBV-associated lymphomas constitute the paradigm of
infection-associated lymphomagenesis, and the understanding of
their pathogenesis has contributed greatly to a better under-
standing of the successive steps leading to lymphoma (Fig. 1).
Neoplastic B-cells are infected by EBV, and lymphomagenesis is
driven by latent viral products that have oncogenic potential.
EBV latency is characterized by a sequential and ﬁnely
controlled pattern of expression of EBV latent genes. Initial
infection of naïve B-cells leads to type III latency, during which
all latent genes are expressed in the cells. Intense proliferation
is driven mostly by latent membrane protein 1 (LMP1), which
mimics the signals normally associated with the engagement of
CD40 on B-cells by CD40L expressed by T-cells during the GC
reaction. Other viral proteins, especially EBV nuclear antigen 2
(EBNA2), transactivate several viral and cellular genes,
contributing to B-cell proliferation. MYC, a potent cellular
oncogene involved in proliferation, is induced by EBNA2. As
infection proceeds, type III latency leads to type II latency,
during which LMP1 and latent membrane protein 2 are still
expressed, but EBNA2 starts to be downregulated, and ﬁnally
the more restricted type I latency, during which only EBV nu-
clear antigen 1 (EBNA1) is expressed in memory B-cells.
EBNA1 is required for the maintenance of the viral episome
during cellular division. Although EBNA1 is not directly onco-
genic, it also plays a role in the process of lymphoid trans-
formation, as EBNA1-deﬁcient EBV has a much lower
transformation efﬁciency [30]. The cellular immune response
mounted after EBV infection effectively counteracts the potent
proliferative effect of EBV on B-cells. EBV-associated post-
























FIG. 1. Simpliﬁed representation of the current models of lymphoid transformation by pathogens. (a) Direct transformation by Epstein–Barr virus
(EBV). Naïve B-cells are targeted by EBV. All infected B-cells harbour the viral episome (circle). Disrupted T-cell control of B-cell proliferation driven
by the expression of viral oncogenes during latency may lead to the development of EBV-associated lymphomas. Alternatively, disrupted regulation of
viral latency in infected B-cells may contribute to the development of EBV-associated lymphomas. (b) Indirect transformation by Helicobacter pylori.
Chronic stimulation by H. pylori leads to persistent proliferation of H. pylori-speciﬁc B-cells and the emergence of B-cell lymphoma cells that remains
dependent on antigen stimulation. Eradication of H. pylori reduces the proliferative signal and leads to regression of the lymphoma. CTL; Hp, Heli-
cobacter pylori; TFH.
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tive CD8+ T-cell functions. In the setting of immune suppres-
sion, the natural process of B-cell proliferation induced by EBV
is unimpeded by CD8+-mediated anti-EBV cytotoxicity. EBV-
associated B-cell lymphoproliferations arise in which EBV
mostly shows type III or type II latency. All endemic Burkitt
lymphomas (BLs), 40% of HIV-associated BLs and 10–20% of
sporadic BLs are also associated with EBV. EBV-associated BL
always shows restricted type I latency, with expression of
EBNA1 alone. BL is universally associated with MYC trans-
locations leading to overexpression of this oncogene. MYC
induces B-cell proliferation, but also induces senescence and
apoptosis, which need to be inhibited during the process of
transformation by several mechanisms, mostly infectious co-
factors such as Plasmodium species, HIV, and EBV. Chronic andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectsustained antigenic stimulation of B-cells, either in the context
of malnourished/immunocompromised children (‘African’ BL),
or in the context of HIV infection (where both HIV and
opportunistic pathogens stimulate the immune system), is
thought to increase the chance of translocations involving Ig
genes and MYC, resulting in BL.
Indirect transformation
The pathogenesis of lymphomas associated with non-
lymphotropic pathogens is, by deﬁnition, different. In such
cases, the pathogen acts only by providing the external cues
that promote proliferation and, with the acquisition of somatic
mutations, the progression towards full-blown transformation.
Chronic and sustained antigenic stimulation is considered to
be the main factor by which non-lymphotropic pathogens canious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 991–997
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for the case of H. pylori-associated gastric MALT lymphoma
(Fig. 1). Indeed, experimental evidence for antigen-induced
proliferation of lymphoma cells has been provided by the
demonstration that cells isolated from H. pylori-associated gastric
MALT lymphoma proliferated in vitro only in the presence of
H. pylori extracts, and T-cells, in a CD40/CD40L-dependent
manner [31]. As mentioned above (‘Mechanisms of lymphoid
transformation’), BCR signalling converges towards the activa-
tion of NF-κB through the multiprotein complex of CARD11,
MALT1, and BCL-10 (CBM complex) [5]. This pathway is also
important in the pathogenesis of gastric MALT lymphomas. The
genes coding for MALT1 and BCL-10 are involved in the
recurrent t(11;18)(q21;q21), t(1;14)(p22;q32) and
t(14;18)(q32;q21) translocations, which lead to the constitutive
activation of the CBM complex. Gastric MALT lymphomas
bearing such translocations are resistant to H. pylori eradication
[32]. Further support for the mechanism of antigen-induced B-
cell proliferation and lymphomagenesis comes from a mouse
model in which cognate (idiotype-dependent) interactions be-
tween B-cells and T-cells can lead to B-cell lymphomas [33].
Interestingly, indirect transformation by H. pylori can also lead to
the development of lymphomas in anatomical sites distinct from
the site of chronic local antigenic stimulation [20].
The mechanism involved in HCV-associated lymphomas
seems to be much more complex. Although, theoretically, HCV
can bind to B-cells, and, in some cases, can be isolated from B-
cells, the evidence supporting B-cell infection by the virus is
inconclusive. CD81, an activation co-receptor expressed on B-
cells, acts as a binding receptor for HCV via an interaction with
the E2 major HCV glycoprotein on the viral particle. E2 is also
the major antigenic target during HCV infection. It has been
suspected that E2 on the surfaces of viral particles could
stimulate B-cells through both BCR and CD81, thus lowering
the threshold of activation and promoting proliferation. A pro-
oncogenic mutator phenotype induced by this stimulation has
also been proposed. Indeed, cells stimulated through both BCR
and E2 were found to show induction of activation-induced
deaminase and nitric oxide synthase, leading to mutations in
p53, BCL-6, and β-catenin, and to show a reduced DNA
damage response [34]. However, conﬂicting results have been
reported. The initial report of a case of HCV-associated B-cell
lymphoma in which neoplastic B-cells bound to E2 was not
conﬁrmed by a larger study [35]. Furthermore, B-cells from
chronically HCV-infected patients were not found to harbour
more mutations in speciﬁc genes, namely those encoding P53,
BCL-6, and β-catenin [36].
The pathophysiology of other non-lymphotropic infection-
associated lymphomas is not well understood, for at least two
reasons. First, the series of patients are not as large as forClinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyH. pylori and HCV. Second, experimental evidence, based on
human samples and animal models, is lacking. However, from
these two examples, a series of factors that seem to be
important to account for the occurrence of these lymphomas
has emerged. A chronic infection, providing a constant source
of antigen, seems to be an important contributory factor.
Therefore the ability of a pathogen to chronically colonize a
mucosal niche is probably a prerequisite for lymphoma devel-
opment. Second, and this is actually linked, a degree of immune
tolerance towards the pathogen is probably also an important
contributory factor, and may result from immunodeﬁciency
and/or immune evasion, by molecular mimicry and/or antigenic
variation.Diagnostic and therapeutic implicationsKnowledge of the pathogens involved in infection-associated
lymphomas is of diagnostic importance in cases where histol-
ogy alone is insufﬁcient to classify the case. This is especially true
for HTLV1 associated adult T-cell leukemia/lymphoma. Although
the morphological and phenotypic features of lymphomas
associated with HTLV1 are well deﬁned, they may be absent. An
elevated proviral load may help in uncertain cases, although the
deﬁnitive proof of association is the demonstration of clonal
integration of the retrovirus in lymphoma cells. These assays are
performed in only a few specialized centres. EBV is easily
detectable by immunohistochemistry (anti-LMP1/latent mem-
brane protein 2 antibodies) and by in situ hybridization (EBV-
encoded small RNA). This method remains the most powerful
demonstration of an association of EBV with lymphoma when
the majority of the lymphoma cells are shown to harbour EBV. It
also helps to determine the latency type (EBV-encoded small
RNA positivity in all cases, and latent membrane protein
expression in latency type II and III). Although a positive EBV
viral load in the blood is not speciﬁc, it can be helpful to monitor
the response to treatment and to allow early relapse [37].
The therapeutic implications are logical. A speciﬁc antimi-
crobial treatment may be indicated, as exempliﬁed by H. pylori-
associated MALT lymphoma [15,38,39]. This line of reasoning
applies to any other antigen-driven lymphoma for which antigen
eradication is expected to decrease lymphoid proliferation,
although the clinical beneﬁt of microbial eradication remains to
be fully established for most other types of antigen-driven
lymphoma.
At present, no therapy directly targeting EBV is available for
EBV-associated lymphomas. Antiviral treatment is effective only
on viral replication during the lytic cycle. However, all EBV-
associated lymphomas harbour latent virus, and depend for
their proliferation on continuous expression of viral latentand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 991–997
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the lytic cycle in EBV lymphomas, in order to restore sensitivity
to antiviral drugs. A phase 1/2 trial of arginine butyrate and
ganciclovir in EBV-associated lymphomas showed some re-
sponses in chemotherapy-refractory patients [40]. An inter-
esting approach is based on inhibition of EBNA1 leading to the
loss of the episome and apoptosis of lymphoma cell lines har-
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